Viridian Therapeutics

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viridian Therapeutics reports strong progress in 2022 with promising trials

Viridian Therapeutics made significant strides in 2022 with positive data on VRDN-001 and plans for Phase 3 trials.
Financially, the company remains strong with $424.6 million in cash, despite increased R&D expenses.
The company's expansion into rare diseases, leadership transition, and strategic clinical site targeting showcase growth potential.
Challenges include dosing frequency impact on efficacy and operational hurdles in patient enrollment and market competition.

Viridian Therapeutics reports strong Q1 performance and strategic advancements

Viridian Therapeutics demonstrated strong performance in clinical trials and financial stability, supported by key hires and strategic partnerships, while facing challenges in investor communication and market access strategies.
The company's focus on innovation in drug delivery methods and pipeline expansion presents opportunities for growth and competitive differentiation in the biopharmaceutical industry.
Overall, Viridian's proactive approach to advancing therapeutic programs and addressing investor concerns positions the company well for future success and potential market impact.

Viridian Therapeutics excels in pipeline progress and financial stability

Viridian Therapeutics showcased strong pipeline progress and financial stability in Q1 2024, with confidence in their transformative therapies.
While facing challenges in regulatory processes and market competition, the company is poised for growth through upcoming program milestones.
Opportunities lie in expanding their therapeutic portfolio, demonstrating product efficacy, and navigating regulatory pathways effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

There were positive results achieved from Viridian Therapeutics, Inc. phase 1/2 study using VRDN-001 for the treatment of patients with chronic thyroid eye disease. Initiation of the phase 3 THRIVE-2 study, using VRDN-001 for the treatment of patients with chronic thyroid eye disease, is expected by Q3 of 2023. Results from the phase 3 THRIVE-2 study, using VRDN-001 for the treatment of patients with chronic thyroid eye disease, are expected by end of 2024.

Viridian: Despite Drop, Advancement Towards Phase 3 Continues

Viridian said its lead therapy helped reduce bulging eyes in thyroid eye disease patients. The biotech specializes in rare diseases and immune disorders.

Why Shares of Viridian Therapeutics Are Falling Tuesday

Shares of VRDN stock collapsed Tuesday after Viridian Therapeutics unveiled the results of its chronic treatment for thyroid eye disease.

Viridian Wants To Take On Horizon; Why This Update In Thyroid Eye Disease Fell Flat

Iovance Biotherapeutics

Futures on the Nasdaq inched higher Tuesday morning. Viridian fell despite announcing some favorable early results from a clinical trial.

Why These 2 Nasdaq Biotech Stocks Fell Hard Tuesday Morning

Shares of Viridian Therapeutics Inc. VRDN, +5.06% fell in the extended session Monday after the biotech drug maker said it was making changes to its study design for a chronic thyroid eye disease therapy. Viridian shares fell more than 17% after hours, following a 5.1% rise to close the regular session at $24.52.

Viridian stock falls more than 15% after drug study update

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive preliminary data from its ongoing Phase 1/2 clinical trial of VRDN-001, an investigational full antagonist antibody to the insulin-like growth factor 1 receptor (IGF-1R), in patients with chronic thyroid eye disease (TED). The Company also announced an amendment to.

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that multiple abstracts featuring data on the Company's lead investigational therapy for the treatment of thyroid eye disease (TED) will be presented at the Annual Meeting of the Endocrine Society (ENDO 2023) to be held June 15-18, 2023, in Chicago, Illinois. An oral present.

Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society

Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Louisa Stone - Manager, IR Scott Myers - President and CEO Kristian Humer - Chief Financial and Business Officer Dr. Thomas Ciulla - Chief Development Officer Todd James - SVP, Corporate Affairs and IR Conference Call Participants Derek Archila - Wells Fargo Gavin Clark-Gartner - Evercore ISI Thomas Smith - SVB Securities Laura Chico - Wedbush Securities Kalpit Patel - B. Riley Securities Jason Butler - JMP Securities Rami Katkhuda - LifeSci Operator Welcome to the Viridian Therapeutics First Quarter 2023 Conference Call.

Viridian Therapeutics, Inc. (VRDN) Q1 2023 Earnings Call Transcript

- Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 -

Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

- Partnership to support one of the Company's preclinical programs outside of thyroid eye disease (TED) - WALTHAM, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse® innovative wearable drug delivery system for volumes of up to 25mL.

Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections

WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Tuesday, May 9, 2023 at 4:30 p.m. ET to discuss its first quarter 2023 financial results and provide a corporate update.

Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023

- Presentations to cover updated clinical and preclinical data on pipeline candidates in Company's thyroid eye disease program -

UPDATE – Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology

Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology

WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Tony Casciano to the role of Chief Commercial Officer (CCO). The Company also announced that Chief Operating Officer (COO) Carrie Melvin is no longer with the organization.

Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer

Viridian Therapeutics, Inc. has been a profitable investment for me. I am trying to get in again.

Viridian: A Second Buying Opportunity, But I Am Waiting For A Better Price

Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q4 2022 Earnings Conference Call March 8, 2023 8:00 PM ET Company Participants Louisa Stone - Manager, Investor Relations Scott Myers - President and Chief Executive Officer Kristian Humer - Chief Financial Officer Deepa Rajagopalan - Chief Product and Strategy Officer Todd James - Senior Vice President, Corporate Affairs and Investor Relations Conference Call Participants Gavin Clark-Gartner - Evercore ISI Laura Chico - Wedbush Securities Jason Butler - JMP Securities Sam Slutsky - LifeSci Capital Kalpit Patel - B. Riley Securities Douglas Tsao - H.C.

Viridian Therapeutics, Inc. (VRDN) Q4 2022 Earnings Conference Call

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -56.94% and 85.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates

- Positive data reported from ongoing Phase 1/2 trial evaluating low-dose VRDN-001 in patients with thyroid eye disease (TED) -

Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

- Data from ongoing Phase 1/2 trial of VRDN-001 to be presented during oral platform session -

Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society

WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, March 8, 2023 at 8:00 a.m. ET to discuss its fourth quarter and full year 2022 financial results.

Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will present at Cowen's 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 1:30 p.m. ET in Boston, MA.

Viridian Therapeutics to Participate in Cowen's 43rd Annual Health Care Conference

WALTHAM, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the SVB Securities Virtual Global Biopharma Conference on Wednesday, February 15, 2023 at 1:00 p.m. ET.

Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

Transition highlights Viridian's progression towards becoming a fully-integrated biopharmaceutical company Transition highlights Viridian's progression towards becoming a fully-integrated biopharmaceutical company

Viridian Appoints Scott Myers as President and Chief Executive Officer

Viridian was one of my top picks in 2022 and it made the 2023 list again. VRDN-001 data continue to impress and Viridian looks well-positioned to disrupt the thyroid eye disease market later this decade.

Why Viridian Therapeutics Is One Of My 2023 Top Picks

- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent with prior 10 and 20 mg/kg results –

News for Viridian Therapeutics Stock (VRDN)